Key result
Antithrombotic medications (except cilostazol) were associated with more frequent bleeding events than no antithrombotic medications in hemodialysis patients.
Why the study?
Do antithrombotic medications increase the risk of bleeding events in hemodialysis patients?
Observational (n=222)
No
Do antithrombotic medications increase the risk of bleeding events in hemodialysis patients?
Antithrombotic medications significantly increase bleeding risk in hemodialysis patients, though cilostazol appears to have the lowest bleeding risk among commonly used agents.
Answers are grounded in this paper and cite their sources.
AM use was associated with more bleeding events in hemodialysis except cilostazol; leaves open differential risk and needs prospective validation.
Antithrombotic medications (AM) are mandatory for many hemodialysis patients, but the bleeding risk associated with this therapy is elevated. The frequency of bleeding events requiring discontinuation of AM, cessation of heparin use, and/or hospitalization was compared between hemodialysis patients with and without AM. All the hemodialysis patients in our clinic were investigated. AM were prescribed in 130 of 222 patients. Except for patients with cilostazol, those with AM had significantly more frequent bleeding events than those without AM (P < 0.01). Bleeding event frequency per 10 000 days of aspirin, clopidogrel, cilostazol, and warfarin prescription was 7.37, 5.95, 2.41, and 9.81, respectively, when restricted to administration of a single AM, which was 4.96, 2.87, 0.7, and 16.06, respectively. In patients without AM, it was 0.91. The bleeding risk associated with AM is elevated in hemodialysis patients and differs markedly depending on the agent used, with the lowest risk associated with cilostazol.
No takes yet. Share an insight, caveat, or question.
Shoichiro Daimon (2018) conducted an observational in Hemodialysis (n=222). Antithrombotic medications vs. No antithrombotic medications was evaluated on Bleeding events requiring discontinuation of antithrombotic medications, cessation of heparin use, and/or hospitalization (p=<0.01). Antithrombotic medications (except cilostazol) were associated with more frequent bleeding events than no antithrombotic medications in hemodialysis patients.
Synapse has enriched 10 related papers. Consider them for comparative context: